Danaher (DHR) Projected to Announce Earnings on Wednesday

Danaher (NYSE:DHR) is anticipated to release its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect the company to announce earnings of $1.92 per share and revenue of $6.56 billion for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 8:00 AM ET.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 EPS. On average, analysts expect Danaher to post $8.53 EPS for the current fiscal year and $9.26 EPS for the next fiscal year.

Danaher Stock Down 0.1%

Danaher stock opened at $228.87 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The firm has a fifty day moving average price of $214.04 and a two-hundred day moving average price of $196.06. The firm has a market cap of $160.89 billion, a price-to-earnings ratio of 40.65, a P/E/G ratio of 2.88 and a beta of 0.76.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Barclays boosted their price objective on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Morgan Stanley increased their target price on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. The Goldman Sachs Group raised their target price on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Finally, Royal Bank Of Canada lifted their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.